310 related articles for article (PubMed ID: 3041218)
1. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.
Rodenhuis S; van de Wetering ML; Mooi WJ; Evers SG; van Zandwijk N; Bos JL
N Engl J Med; 1987 Oct; 317(15):929-35. PubMed ID: 3041218
[TBL] [Abstract][Full Text] [Related]
2. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
3. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.
Rodenhuis S; Slebos RJ; Boot AJ; Evers SG; Mooi WJ; Wagenaar SS; van Bodegom PC; Bos JL
Cancer Res; 1988 Oct; 48(20):5738-41. PubMed ID: 3048648
[TBL] [Abstract][Full Text] [Related]
4. Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer.
Sekine I; Takami S; Guang SG; Yokose T; Kodama T; Nishiwaki Y; Kinoshita M; Matsumoto H; Ogura T; Nagai K
Oncol Rep; 1998; 5(2):351-4. PubMed ID: 9468555
[TBL] [Abstract][Full Text] [Related]
5. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.
Slebos RJ; Kibbelaar RE; Dalesio O; Kooistra A; Stam J; Meijer CJ; Wagenaar SS; Vanderschueren RG; van Zandwijk N; Mooi WJ
N Engl J Med; 1990 Aug; 323(9):561-5. PubMed ID: 2199829
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.
Rosell R; Li S; Skacel Z; Mate JL; Maestre J; Canela M; Tolosa E; Armengol P; Barnadas A; Ariza A
Oncogene; 1993 Sep; 8(9):2407-12. PubMed ID: 8395679
[TBL] [Abstract][Full Text] [Related]
7. K-ras activation in non-small cell lung cancer in the dog.
Kraegel SA; Gumerlock PH; Dungworth DL; Oreffo VI; Madewell BR
Cancer Res; 1992 Sep; 52(17):4724-7. PubMed ID: 1324792
[TBL] [Abstract][Full Text] [Related]
8. Activation of protooncogenes in spontaneously occurring non-liver tumors from C57BL/6 x C3H F1 mice.
Candrian U; You M; Goodrow T; Maronpot RR; Reynolds SH; Anderson MW
Cancer Res; 1991 Feb; 51(4):1148-53. PubMed ID: 1997158
[TBL] [Abstract][Full Text] [Related]
9. Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene.
Goodrow T; Reynolds S; Maronpot R; Anderson M
Cancer Res; 1990 Aug; 50(15):4818-23. PubMed ID: 2196119
[TBL] [Abstract][Full Text] [Related]
10. Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing.
Chong IW; Chang MY; Sheu CC; Wang CY; Hwang JJ; Huang MS; Lin SR
Oncol Rep; 2007 Jul; 18(1):17-24. PubMed ID: 17549340
[TBL] [Abstract][Full Text] [Related]
11. [Detection of K-ras oncogene activation in human lung cancer and its possible clinical application].
Zhang G; Sun Y; Wang M
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Oct; 18(5):282-4, 317. PubMed ID: 8762479
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of ras mutations in human lung cancer. Minireview.
Vachtenheim J
Neoplasma; 1997; 44(3):145-9. PubMed ID: 9372854
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of ras oncogene activation in human lung cancer.
Rodenhuis S; Slebos RJ
Cancer Res; 1992 May; 52(9 Suppl):2665s-2669s. PubMed ID: 1562997
[TBL] [Abstract][Full Text] [Related]
14. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma.
Mills NE; Fishman CL; Rom WN; Dubin N; Jacobson DR
Cancer Res; 1995 Apr; 55(7):1444-7. PubMed ID: 7882350
[TBL] [Abstract][Full Text] [Related]
15. The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors.
Younes N; Fulton N; Tanaka R; Wayne J; Straus FH; Kaplan EL
Cancer; 1997 May; 79(9):1804-8. PubMed ID: 9128999
[TBL] [Abstract][Full Text] [Related]
16. Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer.
Rusch VW; Reuter VE; Kris MG; Kurie J; Miller WH; Nanus DM; Albino AP; Dmitrovsky E
J Thorac Cardiovasc Surg; 1992 Nov; 104(5):1465-9. PubMed ID: 1331621
[TBL] [Abstract][Full Text] [Related]
17. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
[TBL] [Abstract][Full Text] [Related]
18. Molecular staging of non-small cell lung cancer according to K-ras genotypes.
Rosell R; Monzó M; Pifarré A; Ariza A; Sánchez JJ; Moreno I; Maurel J; López MP; Abad A; de Anta JM
Clin Cancer Res; 1996 Jun; 2(6):1083-6. PubMed ID: 9816271
[TBL] [Abstract][Full Text] [Related]
19. ras mutations and expression in head and neck squamous cell carcinomas.
Yarbrough WG; Shores C; Witsell DL; Weissler MC; Fidler ME; Gilmer TM
Laryngoscope; 1994 Nov; 104(11 Pt 1):1337-47. PubMed ID: 7968162
[TBL] [Abstract][Full Text] [Related]
20. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines.
Mitsudomi T; Viallet J; Mulshine JL; Linnoila RI; Minna JD; Gazdar AF
Oncogene; 1991 Aug; 6(8):1353-62. PubMed ID: 1679529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
